Abstract:To the Editor: We report on 15 unrelated patients with clinical suspicion of autosomal recessive limb girdle muscular dystrophy type 2A (LGMD2A; OMIM 253600), referred – with informed consent – for Western blotting of their muscle biopsies and/or mutation screening of the calpain 3 (CAPN3) gene. Four patients (including two sibs) were of Turkish origin; the others came from German ancestry. Clinical data were collected by a retrospective questionnaire and from patients’ medical records. Western blots were analyzed by antibodies to calpain 3 (Clone2C4) and to dystrophin (Dys 2; both from Novocastra Laboratories, Newcastle, UK) in a duplex reaction. Mutation analysis was performed by direct sequencing of all 24 exons of the CAPN3 gene, including the exon–intron boundaries and the promoter region. Nucleotide changes were confirmed either by restriction endonuclease digestion or by cloning of the polymerase chain reaction (PCR) products (TOPO TA cloning kit; Invitrogen, Carlsbad, California, USA) and re-sequencing. Clinical data, results from Western blots, and mutation analyses are summarized in Table 1. Of the 14 mutations detected, nine are novel (Fig. 1, denoted by asterisks) and five have been published previously (1, 2). Deletions 550delA and 598-612del15 were found five and two times, respectively; the rest were private mutations in a single patient each. Exon 8 seems to be most frequently affected in our sample, followed by exons 4, 10, and 21. In total, 64% of mutations fall into these exons. This may help in guiding diagnostic screening strategies. With the exception of two consanguineous families, all other patients were compound heterozygotes (Table 1). None of the sequence changes were detected in 100 control chromosomes. Truncating mutations account for 57% in our sample, whereas missense substitutions all affect evolutionary conserved amino acids (3) and all occur in compound heterozygosity with a null mutation. However, their role in pathogenesis remains to be elucidated. In five patients, only one mutation was detected, and in another three patients with absent or reduced calpain 3 on Western blot, no mutations were found at all. This suggests the presence of heterozygous large deletions which cannot be detected by sequencing of PCR fragments. Such deletions seem not to be rare in the CAPN3 gene (1). Alternatively, mutations may affect non-coding regions or regulatory sequences. One of the patients carry an asyet-unclassified substitution in the promoter region ( 552G!A) which may be responsible for a low calpain 3 expression. We also cannot exclude secondary calpain 3 deficiencies in these three mutation-negative patients. In our sample, the clinical presentation of the myopathy seems to be relatively uniform and characteristic of LGMD2A (Table 1). Normal early motor milestones were registered in all cases, but serum creatine kinase (CK) values were markedly elevated from the beginning. Disease course was generally slow, as only two patients in their thirties have to use a wheel chair. Main difficulty was climbing stairs. Gait abnormalities, walk on toes, weak foot lifters, broad-based gait, and waddling gait were registered in about half of our cases. Spine deformities and contractures are rarely noticed. Weakness of hip adductors and abductors together with the missing involvement of the cardiac and facial muscles may be discriminating features of LGMD2A. Two of the cases with undetected mutations and one case carrying a missense mutation showed a late disease onset after 30 years. Mutations resulting in premature translation termination tend to result in a more severe phenotype with early onset before the age of 15 years. Although the identification of a CAPN3 mutation is of limited value for an individual prognosis of the disease course in LGMD2A, it is indispensable for an exact diagnosis and for genetic counseling of the family. Clin Genet 2005: 67: 356–358 Copyright # Blackwell Munksgaard 2005 Printed in Singapore. All rights reserved CLINICAL GENETICS doi: 10.1111/j.1399-0004.2005.00398.x

Autoimmune enteropathy: molecular concepts

Cochlear implantation for paediatric and adult cases of unilateral and asymmetric hearing loss

Cochlear implantation in children with single-sided deafness under the age of 5 years: a review of current literature

Primary acute glomerular disorders in the elderly.

Electrophysiological Characteristics in Pediatric Cochlear Implantation

X-linked Malformation and Cochlear Implantation

Cochlear implantation in children with inner ear malformations

Determining cochlear implant candidacy in children with residual hearing: A scoping review

In an era of bilateral funding and changing criteria, when is unilateral cochlear implantation a better option?

Early cochlear implantation for children with single sided deafness

Cochlear Implantation in Children with Cochlear Nerve Deficiency: a Report of Nine Cases.

More on the ethical implications of reengineering.

Cochlear Implantation in Children with Single-Sided Deafness: Does Aetiology and Duration of Deafness Matter?

Novel mutations in the calpain 3 gene in Germany

Cochlear implantation for children with single-sided deafness: parents' perspectives

Cranial variation in British mustelids

Cochlear implants in five cases of auditory neuropathy: postoperative findings and progress

Cochlear Implantation in Children with Additional Disabilities: A Systematic Review

Experimental haemorrhagic and endotoxic shock in dogs: evidence for imbalance in exchanges of water and solutes across cell membrane.

A Systematic Review and Meta-analysis Examining Outcomes of Cochlear Implantation in Children With Bilateral Cochlear Nerve Deficiency

Correlation of cochlear aperture stenosis with cochlear nerve deficiency in congenital unilateral hearing loss and prognostic relevance for cochlear implantation